Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IM-1021 (ROR1 ADC) in B-Cell Lymphoma. The expected timing is based on the latest available company guidance and may change.
03/03/26:- Ph1 IM-1021 ongoing in B-cell lymphoma; initial data expected in 2026. 05/13/26:- Phase 1 IM-1021 shows objective responses; initial lymphoma data presentation still expected in 2026. 08/11/26:- Ph1 IM-1021 responses observed at multiple dose levels. Initial lymphoma data expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.